Esophageal Cancer Clinical Trials in Boston, Massachusetts

16 studies are recruiting for esophageal cancer in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

   This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junction or esophageal cancer. Following screening, using a standar…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   16 in total

   Run by

   SOFIE

   See if you can join NCT07217704 on ClinicalTrials.gov

2. A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

   This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test in…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   4 in total

   Run by

   Immunome, Inc.

   See if you can join NCT07578571 on ClinicalTrials.gov

3. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

   This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Tufts Medical Center, Boston, Massachusetts

   Locations

   8 in total

   Run by

   Neonc Technologies, Inc.

   See if you can join NCT06047379 on ClinicalTrials.gov

4. Resilience and Equity in Aging, Cancer, and Health (REACH)

   The purpose of this multi-phase research study is to understand how consultation of cancer care with a geriatrician can best improve outcomes for older adults with gastrointestinal malignancies.

   Stage

   Not phased

   Ages

   65 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT04674267 on ClinicalTrials.gov

5. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   26 in total

   Run by

   SystImmune Inc.

   See if you can join NCT06293898 on ClinicalTrials.gov

6. Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

   The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GE…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Boston, Massachusetts

   Locations

   311 in total

   Run by

   AstraZeneca

   See if you can join NCT07431281 on ClinicalTrials.gov

7. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

8. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

   The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   31 in total

   Run by

   Pfizer

   See if you can join NCT07090499 on ClinicalTrials.gov

9. Serial MRI Scans During Radiation Therapy

   This is a phase 1 study to determine the feasibility and utility of using serial magnetic resonance imaging (MRI) to assess treatment response during and after radiation therapy (standard of care cancer treatment) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulv…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Brigham and Women Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT04188535 on ClinicalTrials.gov

10. A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

    This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a coh…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mass General Cancer Center, Boston, Massachusetts

    Locations

    9 in total

    Run by

    Sutro Biopharma, Inc.

    See if you can join NCT07227168 on ClinicalTrials.gov

11. Distance-Based Exercise to Preserve Function and Prevent Disability

    This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side e…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    18 in total

    Run by

    Alliance for Clinical Trials in Oncology

    See if you can join NCT07059884 on ClinicalTrials.gov

12. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

    This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital - Dana Farber, Boston, Massachusetts

    Locations

    54 in total

    Run by

    Merus B.V.

    See if you can join NCT03526835 on ClinicalTrials.gov

13. A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

    The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital (Data Collection Only), Boston, Massachusetts

    Locations

    10 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06123338 on ClinicalTrials.gov

14. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    6 in total

    Run by

    ModeX Therapeutics, An OPKO Health Company

    See if you can join NCT06239194 on ClinicalTrials.gov

15. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    39 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

16. Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

    The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Lumicell, Inc.

    See if you can join NCT02584244 on ClinicalTrials.gov